当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
HYQVIA, Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase
药品名称
HYQVIA, Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase
承诺描述
Baxter commits to establish and maintain a pregnancy registry to assess a) the course and outcome of the pregnancy, b) the development of the fetus/infant at birth, and c) the development of the infant for two years following birth. The duration of the registry will be six years and will be open to all women who become pregnant while taking HYQVIA.